MAP2K7 and melanoma: Recently several clinical trials evaluated patients with unresectable or metastatic BRAF-mutant melanoma with the combination of BRAF/MEK inhibitors with anti-PD-(L)1 therapy known as triplet therapy (KEYNOTE-022, IMspire150 and COMBI-i).